BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™

BioStem Technologies (OTC: BSEM) has inked an agreement with Venture Medical, a leading US wound market solutions provider, for the nationwide release of its innovative product, AmnioWrap2.

AmnioWrap2 is an advanced biologic skin substitute that is meticulously processed to offer an extensive range of wound healing and wound care solutions.

Jason Matuszewski, BioStem Chairman and CEO, said, “The launch of AmnioWrap2 signifies a pivotal milestone as we expand our spectrum of innovative solutions within the wound care market. We are very pleased to be working with Venture Medical as our commercial partner to bring this versatile product to healthcare providers and patients around the country.”


  • AmnioWrap2 is the latest addition to BioStem’s product portfolio, and is developed using the company’s proprietary BioREtain® This process creates an allograft derived from amniotic tissue, optimized to cater to diverse wound care applications.
  • Venture Medical President, John Schroeder, said, “We are confident that the clinical value created by AmnioWrap2 and the BioREtain® process will quickly translate into rapid physician adoption in office-based and mobile wound care practices.”
  • This month, BioStem also entered an agreement granting NovaBay Pharmaceuticals the right to commercialize BioStem Technologies’ prescription-only Amniotic Tissue Allograft.
  • NovaBay intends to commercialize the prescription-only product as Avenova Allograft. Medically necessary procedures with the Avenova Allograft will be reimbursed through Medicare.
  • To date, BioStem’s wound care products have been utilized in over 30,000 patient applications.

About BioStem Technologies

BioStem is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Its portfolio of quality brands includes VENDAJE®, VENDAJE® AC and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Fla. More information about BioStem Technologies is available here.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™

Catie Corcoran

Biotech Editor